Takeda Pharma launches Rare Disease Therapies in India

Under lysosomal storage disorders, India has been recording the prevalence of Hunter syndrome, Gaucher disease and Fabry disease, Takeda said in a statement.

New Delhi: Takeda Pharmaceutical Company recently said that it has launched an enzyme replacement therapy portfolio for lysosomal storage disorders (LSD) in India, expanding its range of rare disease therapies in the country.

Under lysosomal storage disorders, India has been recording the prevalence of Hunter syndrome, Gaucher disease and Fabry disease, Takeda said in a statement.

Read Also: Novartis buys Takeda dry eye drug Xiidrafor for $3.4 billion

To address these, Takeda brings to the market Idursulfase for Hunter syndrome, Velaglucerase Alpha for Gaucher disease and Agalsidase Alfa for Fabry disease, it added.

"At Takeda, we are committed to patient care by developing innovative new medicines and making existing medicines more readily available," Takeda India Country Head Vineet Singhal said.

Japan-based Takeda focuses on research and development efforts on four therapeutic areas: oncology, gastroenterology (GI), neuroscience and rare diseases.

Read Also: Undeterred by Sanofi stumble, Takeda takes similar path with dengue shot